Format

Send to

Choose Destination
Addict Behav. 2017 Mar;66:132-137. doi: 10.1016/j.addbeh.2016.11.014. Epub 2016 Nov 17.

Beyond methamphetamine: Documenting the implementation of the Matrix model of substance use treatment for opioid users in a South African setting.

Author information

1
Department of Psychiatry, Massachusetts General Hospital (MGH), 1 Bowdoin Square, 7(th) Floor, Boston, MA 02114, USA; Harvard Medical School, 25 Shattuck St, Boston, MA 02115, USA. Electronic address: Jmagidson@mgh.harvard.edu.
2
HIV Mental Health Research Unit, Department of Psychiatry and Mental Health, University of Cape Town, J-Block Groote Schuur Hospital, Anzio Road, Observatory, Cape Town 7925, South Africa.
3
City of Cape Town City Health, PO Box 2815, Cape Town 8000, South Africa.
4
Department of Psychiatry, Massachusetts General Hospital (MGH), 1 Bowdoin Square, 7(th) Floor, Boston, MA 02114, USA.
5
Alcohol Tobacco and Other Drug Research Unit, South African Medical Research Council, Francie Van Zijl Dr, Parow Valley, Cape Town 7501, South Africa; Division of Addiction Psychiatry, Department of Psychiatry and Mental Health, University of Cape Town, J-Block Groote Schuur Hospital, Anzio Road, Observatory, Cape Town 7925, South Africa.
6
University of Miami School of Medicine, Department of Public Health Sciences, 1120 NW 14(th) St., Miami, FL 33136, United States.

Abstract

INTRODUCTION:

The Matrix model of substance use treatment has been evaluated extensively in the United States as an effective treatment for methamphetamine use disorders. Since 2007, the Matrix model has been implemented in Cape Town, South Africa, where one in four treatment-seeking individuals are primarily opioid rather than stimulant users. Yet, there has been limited data on the application of the Matrix model for other types of substance use disorders in a resource-limited setting.

METHODS:

We compared primary opioid and primary methamphetamine users seeking treatment at the first certified Matrix model substance use treatment site in Cape Town, South Africa from 2009 to 2014 (n=1863) on engagement in treatment, an important early predictor of later substance use treatment outcomes, and urine-verified abstinence at treatment exit.

RESULTS:

Compared to primary opioid users, primary methamphetamine users had over 50% greater odds of initiating treatment (defined as attending at least one treatment session following intake; OR=1.55; 95%CI: 1.24-1.94), and 4.5 times greater odds of engaging in treatment (i.e., attending at least four treatment sessions; OR=4.48; 95%CI: 2.27-8.84). There were no significant differences in rates of urine-verified abstinence at treatment exit.

CONCLUSIONS:

Results suggest primary opioid users may experience additional barriers to treatment initiation and engagement in the Matrix model of substance use treatment, yet those who enter treatment are equally as likely to be abstinent at treatment exit compared to primary methamphetamine users. Findings highlight the need for additional strategies to optimize treatment initiation and engagement among primary opioid users in this setting, for instance by integrating medication-assisted treatment (e.g., methadone).

KEYWORDS:

Matrix model; Opioids; Stimulants; Sub-Saharan Africa; Treatment engagement; Treatment initiation

PMID:
27940387
PMCID:
PMC5221678
DOI:
10.1016/j.addbeh.2016.11.014
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center